Application in Cancer treatment (0608) | 賴亮全實驗室

Index

00:00 1.
Application
00:10 2.
How Cancer Arises?
03:14 3.
IntOGen
04:19 4.
GEPIA2
05:42 5.
Benign versus Malignant Tumors
07:20 6.
Classification of Neoplasms
08:32 7.
Metastasis
09:44 8.
Steps of Metastasis
12:10 9.
Major Metastatic Sites and Symptoms
13:37 10.
Grading/Staging of Neoplasms
14:49 11.
Hallmarks of Cancer & Therapeutic Targets
18:17 12.
Pillar of Cancer Therapy
18:35 13.
Surgery
19:14 14.
da Vinci Surgical System
19:40 15.
Type of Radiation
20:15 16.
Radiotherapy
23:41 17.
Particle Therapy
25:23 18.
Chemotherapy
28:56 19.
Immunotherapy
30:32 20.
Innate & Adaptive Immune System
32:26 21.
Adaptive Immune System
36:33 22.
T Cell Receptor
37:29 23.
Adaptive Immune System
38:33 24.
Co-stimulatory Signals
41:54 25.
Immune Checkpoint Inhibitors
44:06 26.
Cytokine Therapy
45:27 27.
Enhancement of APC activity
46:38 28.
Cold tumor to hot tumor
47:46 29.
ESTIMATE
49:10 30.
CIBERSORTx
50:33 31.
Chimeric Antigen Receptor (CAR) T Cells
52:21 32.
Targeted Therapy
53:52 33.
Precision Medicine Initiative
55:01 34.
Era of Precision Medicine
55:32 35.
Goal of Precision Medicine Initiative
56:16 36.
Data Driven Medicine (DDM)
57:02 37.
A New, Quantitative Clinical Marker
58:05 38.
期末報告—互評

Notes (0)

Not logged in or insufficient permissions!

Comment

00:00 1.
Application
00:10 2.
How Cancer Arises?
03:14 3.
IntOGen
04:19 4.
GEPIA2
05:42 5.
Benign versus Malignant Tumors
07:20 6.
Classification of Neoplasms
08:32 7.
Metastasis
09:44 8.
Steps of Metastasis
12:10 9.
Major Metastatic Sites and Symptoms
13:37 10.
Grading/Staging of Neoplasms
14:49 11.
Hallmarks of Cancer & Therapeutic Targets
18:17 12.
Pillar of Cancer Therapy
18:35 13.
Surgery
19:14 14.
da Vinci Surgical System
19:40 15.
Type of Radiation
20:15 16.
Radiotherapy
23:41 17.
Particle Therapy
25:23 18.
Chemotherapy
28:56 19.
Immunotherapy
30:32 20.
Innate & Adaptive Immune System
32:26 21.
Adaptive Immune System
36:33 22.
T Cell Receptor
37:29 23.
Adaptive Immune System
38:33 24.
Co-stimulatory Signals
41:54 25.
Immune Checkpoint Inhibitors
44:06 26.
Cytokine Therapy
45:27 27.
Enhancement of APC activity
46:38 28.
Cold tumor to hot tumor
47:46 29.
ESTIMATE
49:10 30.
CIBERSORTx
50:33 31.
Chimeric Antigen Receptor (CAR) T Cells
52:21 32.
Targeted Therapy
53:52 33.
Precision Medicine Initiative
55:01 34.
Era of Precision Medicine
55:32 35.
Goal of Precision Medicine Initiative
56:16 36.
Data Driven Medicine (DDM)
57:02 37.
A New, Quantitative Clinical Marker
58:05 38.
期末報告—互評

Share
- Embed URL
- QR code

Index
Notes
Comment
Fullscreen

Application in Cancer treatment (0608)

Duration: 59:02, Browse: 412, Last Updated: 2021-06-08

Prev

00:00 1.
Application
00:10 2.
How Cancer Arises?
03:14 3.
IntOGen
04:19 4.
GEPIA2
05:42 5.
Benign versus Malignant Tumors
07:20 6.
Classification of Neoplasms
08:32 7.
Metastasis
09:44 8.
Steps of Metastasis
12:10 9.
Major Metastatic Sites and Symptoms
13:37 10.
Grading/Staging of Neoplasms
14:49 11.
Hallmarks of Cancer & Therapeutic Targets
18:17 12.
Pillar of Cancer Therapy
18:35 13.
Surgery
19:14 14.
da Vinci Surgical System
19:40 15.
Type of Radiation
20:15 16.
Radiotherapy
23:41 17.
Particle Therapy
25:23 18.
Chemotherapy
28:56 19.
Immunotherapy
30:32 20.
Innate & Adaptive Immune System
32:26 21.
Adaptive Immune System
36:33 22.
T Cell Receptor
37:29 23.
Adaptive Immune System
38:33 24.
Co-stimulatory Signals
41:54 25.
Immune Checkpoint Inhibitors
44:06 26.
Cytokine Therapy
45:27 27.
Enhancement of APC activity
46:38 28.
Cold tumor to hot tumor
47:46 29.
ESTIMATE
49:10 30.
CIBERSORTx
50:33 31.
Chimeric Antigen Receptor (CAR) T Cells
52:21 32.
Targeted Therapy
53:52 33.
Precision Medicine Initiative
55:01 34.
Era of Precision Medicine
55:32 35.
Goal of Precision Medicine Initiative
56:16 36.
Data Driven Medicine (DDM)
57:02 37.
A New, Quantitative Clinical Marker
58:05 38.
期末報告—互評

Location

Folder name

Author

賴亮全

Branch

賴亮全教授

Created

2021-06-07 16:52:01

Last Updated

2021-06-08 21:10:36

Duration

59:02